Aug 22 (Reuters) - A Japanese health ministry panel on Monday recommended approval of the Alzheimer's disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month.
The expert panel's decision sets the stage for official approval of the drug, co-developed by Japan's Eisai (4523.T) and U.S.-based Biogen (BIIB.O).
...continue reading